Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.
You may also be interested in...
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.
Following Protest, FDA Accepts Pharmacyclics’ Xcytrin NDA
CEO tells “The Pink Sheet” DAILY data slated for release at upcoming medical conferences could further support approval.